Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Clin Oncol (R Coll Radiol). 2012 Jun;24(5):366-70. doi: 10.1016/j.clon.2012.02.006. Epub 2012 Mar 6.
Primary bone lymphoma is a distinct clinical entity that accounts for 5% of extra-nodal lymphoma. Most patients have diffuse large B-cell lymphoma and present with bone pain, a mass or both. The involvement could be in a single focus or disseminated. There are no prospective clinical studies in this disease. Patients have been treated with radiotherapy, chemotherapy or a combination. There is a trend towards improved outcome with combined modality treatment and further improvement with the addition of rituximab. Assessment of response may be difficult with current imaging techniques. The prognosis of primary bone lymphoma is generally good. Here, the current evidence for the optimal treatment of primary bone lymphoma is reviewed and questions for future investigation are addressed.
原发性骨淋巴瘤是一种独特的临床实体，占结外淋巴瘤的 5%。大多数患者患有弥漫性大 B 细胞淋巴瘤，表现为骨痛、肿块或两者兼有。受累部位可以是单个病灶或弥散性的。在这种疾病中没有前瞻性的临床研究。患者接受了放疗、化疗或联合治疗。联合治疗的趋势是改善预后，加入利妥昔单抗则进一步改善。目前的影像学技术评估反应可能比较困难。原发性骨淋巴瘤的预后一般较好。本文对原发性骨淋巴瘤的最佳治疗方法的现有证据进行了回顾，并提出了未来研究的问题。
